← Issue №14/ week of Oct 4, 2026/IBD

Comparative efficiency of leucine-rich alpha-2 glycoprotein and fecal calprotectin to assess endoscopic activity in Crohn's disease: a prospective observational study.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD prospective cohort · n=84 · Oct 1, 2026 · Inflamm Bowel Dis · IF 4.5

Comparative efficiency of leucine-rich alpha-2 glycoprotein and fecal calprotectin to assess endoscopic activity in Crohn's disease: a prospective observational study.

New evidenceCrohn's diseasebiomarker
Clinical takeawaySerum LRG shows higher sensitivity than FC for endoscopic remission in Crohn’s disease, particularly for small-intestinal lesions, but further validation is needed before clinical adoption.
What it foundLRG had 85.9% sensitivity and 90.0% specificity for endoscopic remission (aSES-CD ≤3) vs 70.3% sensitivity and 85.0% specificity for FC, using cutoffs of 11 µg/mL (LRG) and 100 µg/g (FC).
ContextRefines current practice by suggesting LRG may outperform FC in assessing endoscopic remission, particularly for small bowel involvement, where FC has limitations. However, LRG is not yet validated for widespread use and remains investigational.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Kawamura T … Kawashima H · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues